78
Participants
Start Date
June 30, 2016
Primary Completion Date
October 31, 2021
Study Completion Date
July 31, 2022
PRX-102 (pegunigalsidase alfa)
PRX-102 1 mg/kg every 2 weeks
agalsidase beta
agalsidase beta 1 mg/kg every 2 weeks
Semmelweis Egyetem, Budapest
General Hospital Slovenj Gradec, Slovenj Gradec
Haukeland University Hospital Klinisk Forskningspost, Bergen
Vseobecna fakultni nemocnice v Praze, Prague
Children's Hospital of Pittsburgh, Pittsburgh
Turku University Central Hospital, Turku
O+O Alpan LLC, Fairfax
Emory University School of Medicine, Atlanta
UAB Medicine, Birmingham
Cincinnati Children's Hospital Medical Center, Cincinnati
Infusion Associates, Grand Rapids
Hospital de Dia Quiron Zaragoza, Zaragoza
University of Iowa Hosptials and Clinics, Iowa City
Institute of Metabolic Disease, Baylor Healthcare, Dallas
Renal Disease Research Institute, LLC - Dallas, Dallas
Eccles Primary Children's Outpatient Services Building, Salt Lake City
Phoenix Children's Hospital, Phoenix
University of California San Diego, San Diego
Hôpital Raymond Poincaré, Paris
University of California Irvine Center, Orange
Massachusetts General Hospital, Boston
Medical College of Wisconsin, Milwaukee
"Azienda Ospedaliera Universitaria Federico II", Napoli
Klinik und Poliklinik für Innere Medizin UniversitätsSpital Zürich, Zurich
Institute of Metabolism and Systems Research, Edgbaston
Academisch Medisch Centrum, Amsterdam
Addenbrooke's Hospital, Cambridge
The Royal Free Hospital, London
Salford Royal NHS Foundation Trust, Salford
Chiesi Farmaceutici S.p.A.
INDUSTRY
Protalix
INDUSTRY